Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3686228 | 0.93 | KMT2A (0.45) | MEN1KMT2AALDH1A1NPC1POLB | |
| SCHEMBL1704526 | 0.86 | NPC1 (0.39) | MEN1KMT2AALDH1A1NPC1POLB | |
| SCHEMBL7093467 | 0.81 | ACHE (0.48) | MEN1KMT2AALDH1A1NPC1POLB | |
| SCHEMBL83692 | 0.81 | MEN1 (0.48) | MEN1KMT2AALDH1A1NPC1POLB | |
| SCHEMBL18908535 | 0.81 | MEN1 (0.48) | MEN1KMT2AALDH1A1NPC1POLB | |
| SCHEMBL25385726 | 0.80 | NPY1R (0.33) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL7053663 | 0.79 | NPC1 (0.39) | ALDH1A1NPC1RAB9ASLC6A2SLC6A4 | |
| SCHEMBL7090123 | 0.79 | KDM4E (0.42) | MEN1KMT2AALDH1A1NPC1HTT | |
| SCHEMBL25386051 | 0.79 | CCR5 (0.47) | MEN1KMT2ANPC1RAB9ASLC6A4 | |
| SCHEMBL30377559 | 0.79 | CCR5 (0.47) | MEN1KMT2ANPC1RAB9ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49080-E1 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2022-05-24 | — | — | US | disclosed |
| US-20210284638-A1 | ALPHAvBETA1 INTEGRIN ANTAGONISTS | SAINT LOUIS UNIVERSITY (US) | 2021-09-16 | — | — | US | disclosed |
| US-20210284638-A1 | ALPHAvBETA1 INTEGRIN ANTAGONISTS | SAINT LOUIS UNIVERSITY (US) | 2021-09-16 | — | — | US | disclosed |
| EP-3523293-B1 | SUBSTITUTED PYRROLIDINES AND THEIR USE IN THE TREATMENT OF CYSTIC FIIBROSIS | ABBVIE OVERSEAS SARL (LU) | 2021-06-16 | — | — | EP | disclosed |
| EP-3523293-A1 | SUBSTITUTED PYRROLIDINES AND THEIR USE IN THE TREATMENT OF CYSTIC FIIBROSIS | Abbvie S.a.r.l. (LU) | 2019-08-14 | — | — | EP | disclosed |
| US-9981910-B2 | Substituted pyrrolidines and methods of use | ABBVIE S.Á.R.L. (LU) | 2018-05-29 | — | — | US | disclosed |
| WO-2018065962-A1 | SUBSTITUTED PYRROLIDINES AND THEIR USE IN THE TREATMENT OF CYSTIC FIIBROSIS | AbbVie S.à.r.l. (LU) | 2018-04-12 | — | — | WO | disclosed |
| US-20180099931-A1 | Substituted Pyrrolidines and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2018-04-12 | — | — | US | disclosed |
| US-9895389-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-9895389-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| WO-2006063820-A1 | PYRAZOLO-HETEROARYL COMPOUNDS USEFUL TO TREAT TNF-ALPHA AND IL-1 MEDIATED DISEASES | NOVARTIS AG (CH) | 2006-06-22 | — | — | WO | disclosed |
| EP-1379234-B1 | HALOGENATED AMINOBENZOPHENONES AND AMINOBENZOYLPYRIDINES AS INHIBITORS OF IL-1 AND TNF | NOVARTIS AG (CH) | 2006-03-29 | — | — | EP | disclosed |
| US-6919336-B2 | Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of IL-1 and TNF | NOVARTIS AG (CH) | 2005-07-19 | — | — | US | disclosed |
| US-20040097731-A1 | Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of il-1and tnf | NOVARTIS AG (CH) | 2004-05-20 | — | — | US | disclosed |
| EP-1379234-A1 | HALOGENATED AMINOBENZOPHENONES AND AMINOBENZOYLPYRIDINES AS INHIBITORS OF IL-1 AND TNF | Novartis AG (CH) | 2004-01-14 | — | — | EP | disclosed |
| EP-0665843-B1 | SUBSTITUTED QUINUCLIDINES AS SUBSTANCE P ANTAGONISTS | PFIZER (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002076447-A1 | HALLOGENATED AMINOBENZOPHENONES AND AMINOBENZOYLPYRIDINES AS INHIBITORS OF IL-1 AND TNF | NOVARTIS AG (CH) | 2002-10-03 | — | — | WO | disclosed |
| US-5837711-A | Substituted quinuclidines as substance P antagonists | PFIZER INC. (US) | 1998-11-17 | — | — | US | disclosed |
| EP-0665843-A1 | SUBSTITUTED QUINUCLIDINES AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1995-08-09 | — | — | EP | disclosed |
| WO-1994010170-A1 | SUBSTITUTED QUINUCLIDINES AS SUBSTANCE P ANTAGONISTS | PFIZER INC. (US) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284638-A1 | ALPHAvBETA1 INTEGRIN ANTAGONISTS | ITGB1, ITGAV, ITGA1 | MEN1 2589/4885KMT2A 3675/4885ALDH1A1 441/4885 |
| US-20180099931-A1 | Substituted Pyrrolidines and Methods of Use | CFTR, PKD1, PKD2 | MEN1 3254/4885KMT2A 1882/4885ALDH1A1 586/4885 |
| US-20040097731-A1 | Hallogenated aminobenzophenones and aminobenzoylpyridines as inhibitors of il-1and tnf | TNF, NFKBIA, IL1A | MEN1 1320/4885KMT2A 1573/4885ALDH1A1 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.